• Histologically confirmed, locally advanced (unresectable) or metastatic nonsquamous NSCLC

• Documented absence of tumor activating EGFR mutation, ALK gene and ROS1 rearrangements, and alterations in any actionable driver oncogenes for which there are locally approved targeted first-line therapies

• PD-L1 IHC testing documenting TPS \< 49%

• No prior systemic treatment for advanced/metastatic NSCLC.

• Measurable disease by RECIST 1.1

• ECOG performance status score of 0 or 1

• Life expectancy ≥ 3 months

• Adequate liver, kidney, thyroid and bone marrow function